Diffuse large B-cell lymphoma of waldeyer's ring has distinct clinicopathologic features: A GELA study

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3143-3151

  de Leval, L ^a   Bonnet, C ^b   Copie Bergman, C ^c,d   Seidel, L ^e   Baia, M ^c   Briere J ^f   Molina, T J ^g   Fabiani, B ^h   Petrella, T ⁱ   Bosq, J ^j   Gisselbrecht, C ^f   Siebert, R ^k   Tilly, H ^l   Haioun, C ^c,d   Fillet, G ^b   Gaulard, P ^c,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f SAINT LOUIS HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l UNIVERSITÉ DE ROUEN   (France)

more..

Author keywords

Clinicopathologic features; Diffuse large B cell lymphomas; Outcome; Waldeyer's ring

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; VINCRISTINE;

ADULT; AGED; ARTICLE; BCL2 GENE; BCL6 GENE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IRF4 GENE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE MYC; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TONSIL CANCER; TUMOR BIOPSY; WALDEYER RING;

EID: 84869860262     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds150     Document Type: Article

References (53)

1. d'Amore F, Christensen BE, Brincker H et al. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer 1991; 27: 1201-1208.
2. Swerdlow S, Campo E, Harris N et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2008.
3. Deckert M, Engert A, Bruck W et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 2011; 25: 1797-1807.
4. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011; 118: 2659-2669.
5. Vega F, Lin P, Medeiros LJ. Extranodal lymphomas of the head and neck. Ann Diagn Pathol 2005; 9: 340-350.
6. Reyes F, Lepage E, Ganem G et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-1205.
7. Gospodarowicz MK, Sutcliffe SB, Brown TC et al. Patterns of disease in localized extranodal lymphomas. J Clin Oncol 1987; 5: 875-880.
8. Zucca E, Roggero E, Bertoni F et al. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999; 10: 1023-1033.
9. Krol AD, Le Cessie S, Snijder S et al. Waldeyer's ring lymphomas: a clinical study from the Comprehensive Cancer Center West population based NHL registry. Leuk Lymphoma 2001; 42: 1005-1013.
10. Ree HJ, Kikuchi M, Lee SS et al. Focal follicular features in tonsillar diffuse large B-cell lymphomas: follicular lymphoma with diffuse areas or follicular colonization. Hum Pathol 2002; 33: 732-740.
11. Salaverria I, Philipp C, Oschlies I et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 2011; 118: 139-147.
12. Menarguez J, Mollejo M, Carion R et al. Waldeyer ring lymphomas. A clinicopathlogical study of 79 cases. Histopathology 1994; 24: 13-22.
13. Lopez-Guillermo A, Colomo L, Jimenez M et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005; 23: 2797-2804.
14. Qi S, Li Y, Wang H et al. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation. Cancer 2009; 115: 4980-4989.
15. Shimm D, Dosoretz D, Harris NL et al. Radiation therapy of Waldeyer's ring lymphoma. Cancer 1984; 54: 426-431.
16. Gurkaynak M, Cengiz M, Akyurek S et al. Waldeyer's ring lymphomas: treatment results and prognostic factors. Am J Clin Oncol 2003; 26: 437-440.
17. Ezzat AA, Ibrahim EM, El Weshi AN et al. Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. Head Neck 2001; 23: 547-558.
18. Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N. Treatment results of tonsillar lymphoma: a 10-year experience. Ann Hematol 2005; 84: 223-226.
19. Qin Y, Shi YK, He XH et al. Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil. Chinese J Cancer 2006; 25: 481-485.
20. Laskar S, Bahl G, Muckaden MA et al. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required? Cancer 2007; 110: 816-823.
21. Gisselbrecht C, Lepage E, Molina T et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472-2479.
22. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
23. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.
24. Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 787-792.
25. Morel P, Munck B, Coiffier B. A new high dose CHOP regimen followed by an intensive consolidation in patients (pts) aged ≤60 years with aggressive lymphoma (NHL) presenting with only one adverse prognostic factor of the international prognostic index (IPI). An interim analysis of the LNH93-2 protocol on 433 pts. [Abstract]. Blood 2007; 90: 587a.
26. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-272.
27. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
28. Copie-Bergman C, Gaulard P, Leroy K et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009; 27: 5573-5579.
29. Harabuchi Y, Tsubota H, Ohguro S et al. Prognostic factors and treatment outcome in non-Hodgkin's lymphoma of Waldeyer's ring. Acta Oncol 1997; 36: 413-420.
30. Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
31. Berglund M, Thunberg U, Amini RM et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113-1120.
32. Ott G, Ziepert M, Klapper W et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116: 4916-4925.
33. Huang JZ, Sanger WG, Greiner TC et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285-2290.
34. Bastard C, Deweindt C, Kerckaert JP et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994; 83: 2423-2427.
35. Ott G, Katzenberger T, Lohr A et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade Blood 2002; 99: 3806-3812.
36. Bosga-Bouwer AG, van Imhoff GW, Boonstra R et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003; 101: 1149-1154.
37. Katzenberger T, Ott G, Klein T et al. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol 2004; 165: 481-490.
38. Bosga-Bouwer AG, van den Berg A, Haralambieva E et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol 2006; 37: 528-533.
39. Lorsbach RB, Shay-Seymore D, Moore J et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002; 99: 1959-1964.
40. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. [In process citation]. Nature 2000; 403: 503-511.
41. Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
42. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
43. Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-1837.
44. Rimsza LM, Leblanc ML, Unger JM et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008; 112: 3425-3433.
45. Malumbres R, Chen J, Tibshirani R et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008; 111: 5509-5514.
46. Jais JP, Haioun C, Molina TJ et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22: 1917-1924.
47. Chang CC, McClintock S, Cleveland RP et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464-470.
48. van Imhoff GW, Boerma EJ, van der Holt B et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 4135-4142.
49. Zinzani PL, Dirnhofer S, Sabattini E et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica 2005; 90: 341-347.
50. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-251.
51. Barrans SL, Carter I, Owen RG et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136-1143.
52. Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
53. Iqbal J, Neppalli VT, Wright G et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961-968.